Navigation Links
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Date:8/11/2009

SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced viral load data for the final cohort of hepatitis C patients in a Phase I clinical trial of ANA773, the Company's oral inducer of endogenous interferons that acts via the toll-like receptor 7 (TLR7) pathway. In patients who received 2000 mg ANA773 every other day over 10 days, the mean (+/-SEM) maximal decline in viral load was 1.3 (+/-0.4) log10, compared to a mean maximal decline of 0.3 (+/-0.1) log10 in patients who received placebo (p=0.037). Five of the eight patients who received 2000 mg ANA773 experienced a maximal decline of greater than 1 log, while none of the eight patients who received placebo experienced a decline of greater than 1 log (p<0.001 for the proportion of patients with maximal response greater than 1 log compared to placebo). The mean end-of-treatment decline was 0.6 log10 in patients who received 2000 mg ANA773 compared to 0.1 log10 in patients who received placebo. ANA773 was well-tolerated in patients throughout the course of the study and there were no serious adverse events reported.

"ANA773 has demonstrated a significant short-term antiviral response in HCV patients, comparable to many historical reports of interferon as a single agent," commented Steve Worland, Ph.D., Anadys' President and CEO. "Given its oral delivery and favorable tolerability profile to date, we believe that ANA773 holds promise as a potential replacement for injectable interferon products in HCV therapy. We intend to seek partnership opportunities to continue advancing the development of ANA773, with the objective of creating well-tolerated, all oral combination regimens to treat hepatitis C."

James L. Freddo, M.D., Anadys' Senior Vice President, Drug Development and Ch
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
2. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
3. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
4. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
5. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
6. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
7. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
8. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
9. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
10. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
11. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- According to the new research ... Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical ... NGS, DNA, RNAi) - Global Forecast to 2019" ... is expected to reach $1,712.1 Million by 2019 ... CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" or ... today that it intends to release its financial results ... June 30, 2014 after market trading ends on Tuesday, ... a conference call for 4:30 p.m. U.S. EDT on ... 6:30 a.m. AEST), to review the Company,s financial results, commercial ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Health Care Conference on Wednesday, March 9, 2011 at 11:00 ... Interested parties may access a live webcast of the presentation ... It is recommended that listeners log on 15 ...
... A new ad campaign warns Mississippi legislators that ... prescription drug benefits and undermine the ability of pharmacy ... Mississippi families and businesses, said the Pharmaceutical Care Management ... put the State Board of Pharmacy (instead of the ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2New Ad Campaign: Secret Provision Raises Taxes on Prescription Drug Benefits, Creates 'Conflict of Interest' 2
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an interview ... role as a kicking coach, his kicking business, and on ... retired NFL kicker Michael Husted author of HustedKicking.com. , "Anthony ... one of the top pro free agent kickers out there,” ... at our 2014 Pro Camp and I was impressed with ...
(Date:9/2/2014)... 2014: The fact that mechanical heart valves increase risks ... from the ROPAC registry presented for the first time ... Professor Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall ... 1.4% of pregnant women with a mechanical heart valve ... The Registry Of Pregnancy And Cardiac disease (ROPAC) is ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 “Harmonicas ... about a decade, primarily to help people with ... there are three developed systems,” says Dana Keller, ... substantively differ, the goals are much the same ... of some type of harmonica.” , The three ...
(Date:9/2/2014)... Fast hosting is a great choice for webmasters to ... hosting suppliers and announced that Arvixe, Bluehost and JustHost ... is hard to find a good fast hosting supplier. ... features, uptime, server speed and customer support. People can ... manager of Top10BestSEOHosting.com says. , Arvixe has a world-class ...
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
Breaking Medicine News(10 mins):Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2
... ... ... ... ...
... ... relied on chest x-rays, stress tests, CAT scans and MRIs," said Dr. Myron Licht, ... in better understanding heart failure and cardiopulmonary disease because it provides objective information--primal physiology ... ...
... ... Cleveland medical malpractice attorney nets settlement for widow. , ... Cleveland, OH (PRWEB) February 23, 2010 -- Medical negligence ... reports that he and his firm have obtained a substantial monetary settlement on behalf of ...
... ... ... ... ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 2Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 3Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 4Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 5Health News:Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath 2Health News:Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath 3Health News:Cleveland Medical Malpractice Attorney Obtains Settlement in Wrongful Death Case 2Health News:Cleveland Medical Malpractice Attorney Obtains Settlement in Wrongful Death Case 3Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 2Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 3Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 4Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 5Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 6Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 7Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 2Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 3Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 4Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 5Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 6Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 7Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 2Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 3Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 4Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 5Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 6Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 7
... Our thawing systems are automated, easy to ... from the outside environment by flexible snap-seal ... bacterial or viral contamination of the water. ... the systems can also accommodate bags of ...
Conventional Digitally-Controlled Water Baths...
... a flexible, self-expanding nitinol design intended to ... biliary system, is now available from Cook ... and Drug Administration. Incorporating the features that ... successful around the world, the Zilver 518 ...
... double spot test is a rapid, ... antibodies to T. cruzi in human ... samples. This test is intended primarily ... reactive samples should be confirmed by ...
Medicine Products: